Clinical significance of soluble CD26 in malignant pleural mesothelioma.

Clinical significance of soluble CD26 in malignant pleural mesothelioma.

There is no established single diagnostic marker for malignant pleural mesothelioma (MPM). CD26 is a 110 kDa, multifunctional, membrane-bound glycoprotein that has dipeptidyl peptidase IV (DPPIV) enzyme activity. The aim of this study was to evaluate the clinical significance of soluble CD26 (sCD26)...

Full description

Bibliographic Details
Main Authors:	Nobukazu Fujimoto, Kei Ohnuma, Keisuke Aoe, Osamu Hosono, Taketo Yamada, Takumi Kishimoto, Chikao Morimoto
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0115647&type=printable

Similar Items

Physician requests by patients with malignant pleural mesothelioma in Japan
by: Yasuko Nagamatsu, et al.
Published: (2019-04-01)

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study
by: Yasuko Nagamatsu, et al.
Published: (2018-03-01)

An appropriate choice for immunotherapy in malignant pleural mesothelioma
by: Nobukazu Fujimoto
Published: (2020-12-01)

Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma
by: Takamasa Nakasuka, et al.
Published: (2015-01-01)

Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
by: Riki Okita, et al.
Published: (2024-07-01)

Phrenic Nerve Paralysis as the Initial Presentation in Pleural Sarcomatoid Mesothelioma
by: Go Makimoto, et al.
Published: (2014-06-01)

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
by: Kazuhiko Nakagawa, MD, PhD, et al.
Published: (2021-06-01)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
by: Nobukazu Fujimoto, et al.
Published: (2020-05-01)

Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion
by: Takumi Kishimoto, et al.
Published: (2021-06-01)

Malignant pleural mesothelioma
by: Rao Sukhesh
Published: (2009-01-01)

Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
by: Takaaki Tanaka, MD, et al.
Published: (2022-07-01)

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients
by: Takumi Kishimoto, et al.
Published: (2019-12-01)

Clinical Investigation of Benign Asbestos Pleural Effusion
by: Nobukazu Fujimoto, et al.
Published: (2015-01-01)

Immunotherapy in Malignant Pleural Mesothelioma
by: Cornedine J. de Gooijer, et al.
Published: (2020-02-01)

Malignant pleural mesothelioma with resolution of pleural effusion
by: Sayaka Nishida, et al.
Published: (2023-11-01)

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
by: Yutaro Kaneko, et al.
Published: (2021-03-01)

Functional Properties of CD8+ Lymphocytes in Patients with Pleural Plaque and Malignant Mesothelioma
by: Naoko Kumagai-Takei, et al.
Published: (2014-01-01)

KRAS signaling in malignant pleural mesothelioma
by: Antonia Marazioti, et al.
Published: (2021-12-01)

Malignant pleural mesothelioma in a child
by: Jed Brendan Scharf, et al.
Published: (2015-10-01)

Advances in Immunotherapy for Malignant Pleural Mesothelioma
by: Yujia CHI, et al.
Published: (2022-04-01)

Pleural amyloidosis mimicking malignant mesothelioma
by: Min Yeong Kim, et al.
Published: (2017-06-01)

Duodenal Metastasis of Malignant Pleural Mesothelioma
by: Huang-Chi Chen, et al.
Published: (2008-12-01)

Pleural tuberculosis mimicking malignant mesothelioma
by: Wajahat Dawood, et al.
Published: (2020-01-01)

Circulating biomarkers in malignant pleural mesothelioma
by: Giuseppe Viscardi, et al.
Published: (2020-12-01)

Modern management of malignant pleural mesothelioma
by: Patel SC, et al.
Published: (2016-05-01)

Diagnosis and Treatment of Malignant Pleural Mesothelioma
by: Zhilong ZHAO, et al.
Published: (2009-01-01)

ECM Mechanoregulation in Malignant Pleural Mesothelioma
by: Valeria Panzetta, et al.
Published: (2022-02-01)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
by: Nobukazu Fujimoto, MD, PhD, et al.
Published: (2021-03-01)

Pleural involvement of diffuse large B-cell lymphoma mimicking malignant pleural mesothelioma
by: Takanori Ito, et al.
Published: (2020-01-01)

Advances in Targeted Therapy for Malignant Pleural Mesothelioma
by: Fen FU, et al.
Published: (2024-05-01)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
by: Shantanu Banerji, et al.
Published: (2021-11-01)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
by: Jacopo Moro, et al.
Published: (2022-12-01)

Malignant pleural mesothelioma with rarely seen metastases
by: Elif Şenocak Taşçı, et al.
Published: (2017-12-01)

European guidelines for the management of malignant pleural mesothelioma
by: Eric van Thiel, et al.
Published: (2011-10-01)

Advances in diagnosis and treatment of malignant pleural mesothelioma
by: Giorgio Vittorio Scagliotti, et al.
Published: (2011-12-01)

Advances in diagnosis and treatment of malignant pleural mesothelioma
by: Giorgio Vittorio Scagliotti, et al.
Published: (2011-12-01)

Chondrosarcoma of the Rib Mimicking Malignant Pleural Mesothelioma
by: Masashi Furukawa, et al.
Published: (2016-01-01)

How I treat malignant pleural mesothelioma
by: Floriana Morgillo, et al.
Published: (2019-05-01)

Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma
by: Agnes Y. Choi, et al.
Published: (2022-05-01)

Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
by: Eiji Takeuchi, et al.
Published: (2020-10-01)